RSPI (RespireRx Pharmaceuticals) Stock Based Compensation: $0.00 Mil (TTM As of Sep. 2023)


RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals Stock Based Compensation?

RespireRx Pharmaceuticals RSPI 12 Stock Based Compensation is $0.00 Mil as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

RespireRx Pharmaceuticals's Stock Based Compensation for the three months ended in Sep. 2023 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

RespireRx Pharmaceuticals Stock Based Compensation Related Terms

RespireRx Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Stock Based Compensation Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.00 0.38 0.06 0.00

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Stock Based Compensation of $0.00 Mil mean?
RespireRx Pharmaceuticals (RSPI) has a Stock Based Compensation of $0.00 Mil as of Sep. 2023. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' Stock Based Compensation too high?
RespireRx Pharmaceuticals' current Stock Based Compensation is $0.00 Mil. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' Stock Based Compensation compare to CNBX and NAVB?
RespireRx Pharmaceuticals' Stock Based Compensation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current Stock Based Compensation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current Stock Based Compensation of $0.00 Mil. The current Stock Based Compensation is $0.00 Mil. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Stock Based Compensation is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price